The global challenge of new classes of antibacterial agents: An industry perspective

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 7-11

  Fernandes, Prabhavathi ^a  

^a Cempra Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; GENERIC DRUG; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; ANTIINFECTIVE AGENT;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLOSTRIDIUM DIFFICILE INFECTION; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MISUSE; DRUG PENETRATION; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; INFECTION; INFECTION PREVENTION; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; RAPID TEST; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; VISUAL DISORDER; VOMITING; ANIMAL; DRUG DEVELOPMENT; DRUG INDUSTRY; MOTIVATION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; HUMANS; MOTIVATION;

EID: 84935002928     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.06.003     Document Type: Review

References (49)

1. Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States 2013 2013 1 114
2. World Health Organization WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health 2014
3. C.G. Giske, D.L. Monnet, O. Cars, and Y. Carmeli Clinical and economic impact of common multidrug-resistant gram-negative bacilli Antimicrob Agents Chemother 52 2008 813 821
4. R.L. Finley, P. Collignon, D.G. Larsson, S.A. McEwen, X.Z. Li, W.H. Gaze, R. Reid-Smith, M. Timinouni, D.W. Graham, and E. Topp The scourge of antibiotic resistance: the important role of the environment Clin Infect Dis 57 2013 704 710
5. C. Nathan, and O. Cars Antibiotic resistance-problems, progress, and prospects N Engl J Med 371 2014 1761 1763
6. Food and Drug Administration Combating Antibiotic Resistance 2011 1-2
7. President's Council of Advisors on Science and Technology (PCAST): Report to the President on Combating Antibiotic Resistance. Washington, DC; 2014:1-78.
8. A. Carr, and M. Vignola Cubist Pharma's Buys Look Like Square Deals 2013 In Barron's
9. V.L. Nathan, and B. Hirschler Merck to take on superbugs with Cubist Pharma buy 2014 Reuters 1 2
10. A three-step plan for antibiotics Nature 509 2014 533
11. J.L. Fox Federal officials, congress seek ways to stimulate antibiotic development Microbe 10 2015 13 16
12. M. Woolhouse, and J. Farrar Policy: an intergovernmental panel on antimicrobial resistance Nature 509 2014 555 557
13. D.M. Shlaes, D. Sahm, C. Opiela, and B. Spellberg The FDA reboot of antibiotic development Antimicrob Agents Chemother 57 2013 4605 4607
14. New drugs way to avoid an antibiotic apocalypse Financial Times 2015
15. L.A. McAllister, J.I. Montgomery, J.A. Abramite, U. Reilly, M.F. Brown, J.M. Chen, R.A. Barham, Y. Che, S.W. Chung, C.A. Menard, and et al. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents Bioorg Med Chem Lett 22 2012 6832 6838
16. J. Wang, S. Kodali, S.H. Lee, A. Galgoci, R. Painter, K. Dorso, F. Racine, M. Motyl, L. Hernandez, E. Tinney, and et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties Proc Natl Acad Sci U S A 104 2007 7612 7616
17. S. Langklotz, M. Schakermann, and F. Narberhaus Control of lipopolysaccharide biosynthesis by FtsH-mediated proteolysis of LpxC is conserved in enterobacteria but not in all gram-negative bacteria J Bacteriol 193 2011 1090 1097
18. J.A. Sutcliffe Antibiotics in development targeting protein synthesis Ann N Y Acad Sci 1241 2011 122 152
19. T.V. Magee, S.L. Ripp, B. Li, R.A. Buzon, L. Chupak, T.J. Dougherty, S.M. Finegan, D. Girard, A.E. Hagen, M.J. Falcone, and et al. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections J Med Chem 52 2009 7446 7457
20. H.W. Boucher, G.H. Talbot, D.K. Benjamin Jr., J. Bradley, R.J. Guidos, R.N. Jones, B.E. Murray, R.A. Bonomo, and D. Gilbert 10 x '20 Progress - development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America Clin Infect Dis 56 2013 1685 1694
21. D. Pavlovic, and S. Mutak Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides J Med Chem 53 2010 5868 5880
22. A.B. Shapiro, J. Newman, K. Goteti, M.E. Beaudoin, R. Harrison, S. Hopkins, N. Agrawal, and O. Rivin Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes Antimicrob Agents Chemother 57 2013 4816 4824
23. A.F. Widmer Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 2008 656 658
24. H. Plumridge Drug makers tiptoe back into antibiotic R&D Wall Street J 2014
25. P. Fernandes Antibacterial discovery and development - the failure of success? Nat Biotechnol 24 2006 1497 1503
26. C.J. Currie, E. Berni, S. Jenkins-Jones, C.D. Poole, M. Ouwens, S. Driessen, H. de Voogd, C.C. Butler, and C.L. Morgan Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis BMJ 349 2014 g5493
27. C.L. Trotter, J.M. Stuart, R. George, and E. Miller Increasing hospital admissions for pneumonia, England Emerg Infect Dis 14 2008 727 733
28. M.K. Freeman Community-Acquired Bacterial Pneumonia: A Primer for Pharmacists 2013 U.S. Pharmacist p. 38
29. C.A. Reynolds, J.A. Finkelstein, G.T. Ray, M.R. Moore, and S.S. Huang Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia: a cost analysis Antimicrob Resist Infect Control 3 2014 16
30. L.L. Ling, T. Schneider, A.J. Peoples, A.L. Spoering, I. Engels, B.P. Conlon, A. Mueller, T.F. Schaberle, D.E. Hughes, S. Epstein, and et al. A new antibiotic kills pathogens without detectable resistance Nature 517 2015 455 459
31. C. Sun, D.K. Hunt, R.B. Clark, D. Lofland, W.J. O'Brien, L. Plamondon, and X.Y. Xiao Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs J Med Chem 54 2011 3704 3731
32. C. Sun, Q. Wang, J.D. Brubaker, P.M. Wright, C.D. Lerner, K. Noson, M. Charest, D.R. Siegel, Y.M. Wang, and A.G. Myers A robust platform for the synthesis of new tetracycline antibiotics J Am Chem Soc 130 2008 17913 17927
33. P.M. Wright, I.B. Seiple, and A.G. Myers The evolving role of chemical synthesis in antibacterial drug discovery Angew Chem Int Ed Engl 53 2014 8840 8869
34. D. Becker, M. Selbach, C. Rollenhagen, M. Ballmaier, T.F. Meyer, M. Mann, and D. Bumann Robust Salmonella metabolism limits possibilities for new antimicrobials Nature 440 2006 303 307
35. O.J. Naderer, E. Dumont, J. Zhu, M. Kurtinecz, and L.S. Jones Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor Antimicrob Agents Chemother 57 2013 2005 2009
36. K. O'Dwyer, M. Hackel, S. Hightower, D. Hoban, S. Bouchillon, D. Qin, K. Aubart, M. Zalacain, and D. Butler Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322 Antimicrob Agents Chemother 57 2013 2333 2342
37. F.C. Lessa, Y. Mu, W.M. Bamberg, Z.G. Beldavs, G.K. Dumyati, J.R. Dunn, M.M. Farley, S.M. Holzbauer, J.I. Meek, E.C. Phipps, and et al. Burden of Clostridium difficile infection in the United States N Engl J Med 372 2015 825 834
38. Y.S. Krishnaiah Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs J Bioequiv Availab 2 2010 28 36
39. G.R. Corey, M. Wilcox, G.H. Talbot, H.D. Friedland, T. Baculik, G.W. Witherell, I. Critchley, A.F. Das, and D. Thye Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
40. S. Reardon Phage therapy gets revitalized Nature 510 2014 15 16
41. M.B. Oleksiewicz, G. Nagy, and E. Nagy Anti-bacterial monoclonal antibodies: back to the future? Arch Biochem Biophys 526 2012 124 131
42. R.E. Hancock, A. Nijnik, and D.J. Philpott Modulating immunity as a therapy for bacterial infections Nat Rev Microbiol 10 2012 243 254
43. P.A. Waight, N.J. Andrews, S.N. Ladhani, C.L. Sheppard, M.P.E. Slack, and E. Miller Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study Lancet Infect Dis 15 2015 535 543
44. D.P. Levine Vancomycin: a history Clin Infect Dis 42 Suppl 1 2006 S5 S12
45. D.B. Ross The FDA and the case of Ketek N Engl J Med 356 2007 1601 1604
46. D. Bertrand, S. Bertrand, E. Neveu, and P. Fernandes Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors Antimicrob Agents Chemother 54 2010 5399 5402
47. C.A. Ison, K. Town, C. Obi, S. Chisholm, G. Hughes, D.M. Livermore, and C.M. Lowndes Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011 Lancet Infect Dis 13 2013 762 768
48. N. Goire, M.M. Lahra, M. Chen, B. Donovan, C.K. Fairley, R. Guy, J. Kaldor, D. Regan, J. Ward, M.D. Nissen, and et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance Nat Rev Microbiol 12 2014 223 229
49. A.R. Flores, J. Galloway-Pena, P. Sahasrabhojane, M. Saldana, H. Yao, X. Su, N.J. Ajami, M.E. Holder, J.F. Petrosino, E. Thompson, and et al. Sequence type 1 group B Streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes Proc Natl Acad Sci USA 112 2015 6431 6436